Program
tivunatamig
Also written as “PF-08634404” and “SSGJ-707”.
In Pfizer’s pipeline, PD-1xVEGF Bispecific Antibody
. Its studies are mostly in Endometrial Neoplasms · Small Cell Lung Carcinoma · Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Stomach Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 1010 open or running | phase 3since Oct 28, 2025 | Oct 28, 2025 | Oct 18, 2027phase 2 · NCT07227012 |
| 3SBio | 55 open or running | phase 3since May 12, 2025 | Apr 8, 2024 | none ahead |
- Named in Pfizer’s own pipeline as
tivunatamig PF-08634404
, phase 3, as of Nov 3, 2026 (source).
Also a collaborator on its studies: Astellas Pharma.
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicensePfizer licensed it from 3SBio, for everywhere outside China, with an option on China.Announced May 19, 2025 · Source: Pfizer (release), May 19, 2025
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. Dates ahead are the sponsors’ estimates.
- Apr 8, 2024First studies: 2 phase 2 studiesNew to 3SBio3SBio · NCT06361927, NCT06412471
- Jun 25, 2024Phase 2 study in Colorectal Neoplasms3SBio · NCT06493760 · 130 planned · China
- Jul 22, 2024Phase 2 study in Endometrial Neoplasms3SBio · NCT06522828 · 80 planned · China
- May 12, 2025Phase 3 study in Advanced Non-Small Cell Lung Cancer3SBio · NCT06980272 · 420 planned · China
- May 19, 2025Pfizer licensed it from 3SBioLicenseEverywhere outside China, with an option on China · announced · Pfizer (release)
- Oct 28, 2025Pfizer’s first studies: 2 phase 3 studiesNew to PfizerPfizer · NCT07222800, NCT07222566
- Nov 7, 20252 phase 2 studiesPfizer · NCT07227415, NCT07227012
- Nov 7, 2025Phase 3 study in Small Cell Lung CarcinomaPfizer · NCT07226999 · 550 planned · United States, Australia, China and more
- Jan 30, 2026Phase 3 study in Stomach NeoplasmsPfizer · NCT07392892 · 840 planned · United States, Canada, China and more
- Feb 12, 2026Phase 2 study in Carcinoma, Transitional CellPfizer · NCT07421700 · 132 planned · United States, Australia, China and more
- Mar 13, 20262 phase 2 studiesPfizer · NCT07476287, NCT07489066
- May 5, 2026Phase 3 study in Endometrial NeoplasmsPfizer · NCT07578649 · 600 planned · United States, Australia, China and more
- Sep 28, 2026Primary completion moved from 2031-07-22 to 2032-01-15Date moved laterphase 3 · +6 months · NCT07392892
Ahead
- Oct 18, 2027Primary completion: phase 2 study in Carcinoma, HepatocellularPfizer · NCT07227012
- Nov 2, 2027Primary completion: phase 2 study in Carcinoma, Renal CellPfizer · NCT07227415
- Dec 28, 2027Primary completion: phase 2 study in Carcinoma, Transitional CellPfizer · NCT07421700
- Mar 24, 2028Primary completion: phase 2 study in Small Cell Lung CarcinomaPfizer · NCT07476287
TargetBeta
“PD-1xVEGF Bispecific Antibody”the company's pipeline, read by Claude · source
“A humanized immunoglobulin G4 (IgG4) bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and human vascular endothelial growth factor (VEGF), with potential immune checkpoint inhibitory, anti-angiogenic and an…”NCIt, read by Claude
“A humanized immunoglobulin G4 (IgG4) bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and human vascular endothelial growth factor (VEGF), ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14rule | Sinocelltech Group | phase 3 | 2 |
| ABBV-1480 | RemeGen | phase 3 | 2 |
| Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001rule | Sichuan Kelun Pharmaceutical | phase 2 | 4 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody MK-2010 | Merck | phase 2 | 4 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody MHB039Arule | Minghui Pharmaceutical | phase 2 | 3 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody JS207rule | wigen-biomedicine-technology-shanghai-co-ltd | phase 2 | 2 |
| Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rule | hc-biopharma-inc | phase 2 | 2 |
| Anti-PD-1/Anti-VEGF-A Bispecific Antibody CTX-10726rule | compass-therapeutics | phase 1 | 1 |
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07578649Endometrial Neoplasms · United States, Australia, China and more | 3 | Recruiting | Pfizer | Jun 1, 2029 | 600 |
| NCT07489066Carcinoma · United States, Australia, China and more | 2 | Recruiting | Pfizer | Jul 29, 2028 | 120 |
| NCT07476287Small Cell Lung Carcinoma · United States, Australia, Brazil and more | 2 | Recruiting | Pfizer | Mar 24, 2028 | 40 |
| NCT07421700Carcinoma, Transitional Cell · United States, Australia, China and more | 2 | Recruiting | Pfizer | Dec 28, 2027 | 132 |
| NCT07392892Stomach Neoplasms · United States, Canada, China and more | 3 | Recruiting | Pfizer | Jul 22, 2031 | 840 |
| NCT07227415Carcinoma, Renal Cell · United States, Australia, China and more | 2 | Recruiting | Pfizer | Nov 2, 2027 | 224 |
| NCT07227012Carcinoma, Hepatocellular · United States, China, Japan and more | 2 | Recruiting | Pfizer | Oct 18, 2027 | 138 |
| NCT07226999Small Cell Lung Carcinoma · United States, Australia, China and more | 3 | Recruiting | Pfizer | Jun 14, 2030 | 550 |
| NCT07222800Intestinal Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Pfizer | Feb 23, 2030 | 800 |
| NCT07222566Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Recruiting | Pfizer | Feb 27, 2029 | 1,410 |
| NCT06980272Advanced Non-Small Cell Lung Cancer · China | 3 | Recruiting | 3SBio | Jul 30, 2026 | 420 |
| NCT06522828Endometrial Neoplasms · China | 2 | Recruiting | 3SBio | Aug 2025 | 80 |
| NCT06493760Colorectal Neoplasms · China | 2 | Recruiting | 3SBio | Jun 2025 | 130 |
| NCT06412471First-line Advanced NSCLC Patients · China | 2 | Recruiting | 3SBio | Jul 2025 | 235 |
| NCT06361927NSCLC · China | 2 | Recruiting | 3SBio | Jun 2025 | 120 |
How it is read
Names in the registry
- “PF-08634404”, 10 entries
- “SSGJ-707”, 5 entries
Conditions, from the studies’ own filings
- Endometrial Neoplasms, 2 studies
- Small Cell Lung Carcinoma, 2 studies
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Colorectal Neoplasms, 2 studies
- Stomach Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.